• Like
  • Comment
  • Favorite

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA China

Reuters01-20

Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:

  • GOT DRUG APPROVAL FOR SKB445 BY NMPA CHINA

Further company coverage: 6990.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

empty
No comments yet
errorbox banner

抱歉,当前请求异常(-1)

7x24

  • 21:56

    Fastighets Ab Balder - to Distribute Entire Holding of Norion Bank Shares as Dividend

  • 21:54

    Avolon Announces Pricing of US$850 Million Senior Unsecured Notes Offering

  • 21:49

    Ascot Reports 2024 Annual Results

  • 21:40

    White Energy Company Ltd-Entitlement Offer - Results

  • 21:40

    Ampol - About Half of Lytton Refinery Costs Expected to Be Recovered Through Insurance

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial